InvestSMART

Imugene Limited (ASX:IMU)

ALERT: Price-sensitive ASX Announcement for IMU
Current share price for IMU : $0.093 -0.003 (-3.13%)+
Announcement
Release
22 May 2026 9:27AM
Price at Release
$0.096
Full Release
download
Summary
Imugene Limited has released promising data on Azer-cel from a Phase 1b study involving a CAR T naive cohort, presented in an abstract at ASCO 2026. The study demonstrates significant clinical activity across various CD19 B-cell malignancies such as marginal zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL), with an overall response rate (ORR) of 81%. The data highlights robust CAR T-cell expansion and a favorable safety profile. The company plans to present updated results at the ASCO Annual Meeting, emphasizing Azer-cel's potential in delivering substantial clinical benefits across specific cancer indications.
Key Points
  • Azer-cel demonstrates promising clinical activity across CD19 B-cell malignancies including MZL and CLL.
  • Encouraging response rates, robust CAR T-cell expansion, and a manageable safety profile observed.
  • Overall response rate (ORR) was 81% among evaluable patients in the CAR T naïve cohort.
  • Azer-cel Phase 1b study data presented in ASCO 2026 abstract.
  • Imugene to present updated data in an oral presentation at the ASCO Annual Meeting.
  • Imugene's trial aims to target specific indications where Azer-cel can have a strong clinical impact.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.